Apr. 10, 2024
Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy
Teijin Pharma Limited
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp